iOnctura Company

iOnctura is a late stage preclinical biotechnology company developing a pipeline of next generation, best-in-class molecules for the treatment of cancer and fibrosis.

iOnctura is developing a pipeline of carefully selected assets. Programs in oncology aim to harness both immune-mediated and direct anti-tumour activity to deliver superior clinical efficacy in monotherapy or combinations. By building on complementary mechanisms between cancer and fibrosis iOnctura further aims to address high unmet need in fibrotic disease.
Technology: P4 Medicine
Industry: P4 Medicine
Headquarters: Genève, Geneve, Switzerland
Founded Date: 7-9
Employees Number: 1-10
Funding Status: Early Stage Venture
Investors Number: 5
Total Funding: €20.1M
Estimated Revenue: $1M to $10M
Last Funding Type: Series A

Visit Website
info@iOnctura.com
Register and Claim Ownership